智通财经网·2026-01-08 01:12Core Viewpoint - Eli Lilly (LLY.US) has agreed to acquire Ventyx Biosciences (VTYX.US) for $14 per share in cash, with a total equity value of approximately $1.2 billion, aiming to expand its immunology business [1][1][1] Group 1: Acquisition Details - The acquisition is expected to be completed in the first half of this year and does not include any financing conditions [1][1] - Bank of America Securities is serving as the exclusive financial advisor to Eli Lilly, while Jefferies is the lead financial advisor for Ventyx [1][1] Group 2: Strategic Rationale - Eli Lilly aims to enhance its immunology portfolio, which is identified as a key growth area for the company [1][1] - The company has successfully attracted investor and patient interest in diabetes and obesity treatments, and is looking to further expand its offerings [1][1] Group 3: Current Product Landscape - Eli Lilly currently markets several drugs for inflammatory diseases, including Taltz, although the key patent for Taltz is set to expire in the coming years [1][1] - The company has previously made significant acquisitions, including a $3.2 billion purchase of Morphic Therapeutics for an experimental drug targeting inflammatory bowel disease and a $2.4 billion acquisition of Dice Therapeutics, which develops oral therapies for psoriasis [1][1]